Standard BioTools and Treeline Biosciences Announce Merger Agreement

Expected Cash at Closing

$900 million

Pro-forma cash expected to support operations into 2029.

Merger Value

$460 million

Estimated value of Standard BioTools based on net cash delivered at closing plus $10 million.

Ownership Post-Merger

16% / 84%

Ownership distribution between pre-merger Standard BioTools and Treeline stockholders.

§ 01 Executive Snapshot

What: Standard BioTools and Treeline Biosciences announced a definitive merger agreement to combine operations.
Who: Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc., led by Josh Bilenker, MD.
Why it matters: The merger aims to create a robust biopharma company with a deep pipeline and significant financial resources to advance drug development.

The combined company will operate under the name Treeline Biosciences and trade on Nasdaq under the ticker symbol "TRLN."
At closing, the combined entity is expected to have over $900 million in cash, providing operational runway into 2029.
Treeline’s pipeline includes three Phase 1 programs, with interim data readouts expected starting in 2027.

Treeline has developed a productive in-house discovery and development organization since its founding in 2021, focusing on oncology, neurology, and immunology.
The merger reflects a strategic initiative to maximize shareholder value and enhance the combined company's capabilities in drug development.

Immediate implications include a strengthened balance sheet that will support the advancement of multiple clinical programs.
Long-term, the merger positions the combined company to capitalize on transformative data readouts and expand its clinical pipeline significantly.

Potential risks include regulatory hurdles and the execution of the merger under customary closing conditions.
There is uncertainty surrounding the future performance of Standard BioTools’s Mass Cytometry and Microfluidics businesses, which Treeline does not intend to operate.

The transaction is expected to close in the second half of 2026, pending regulatory approvals and shareholder votes.
Key milestones will include interim clinical data readouts in 2027 and the launch of additional clinical programs in 2027 and 2028.

§ 07

What companies are merging?

Standard BioTools Inc. and Treeline Biosciences, Inc. are merging.

Why is the merger important?

The merger aims to create a robust biopharma company with significant financial resources to advance drug development.

When is the merger expected to close?

The transaction is expected to close in the second half of 2026, pending regulatory approvals and shareholder votes.

What will the combined company be called?

The combined company will operate under the name Treeline Biosciences and trade on Nasdaq under the ticker symbol 'TRLN'.